Recombinant Mycoplasma pneumoniae Valine--tRNA ligase (valS), partial

What is the functional significance of the partial valS protein compared to the full-length enzyme in Mycoplasma pneumoniae?

The partial valS protein represents a truncated but functionally relevant segment of the complete Valine--tRNA ligase from Mycoplasma pneumoniae. This aminoacyl-tRNA synthetase plays a critical role in protein synthesis by attaching valine to its cognate tRNA molecules. Mycoplasma pneumoniae, as one of the smallest known free-living microorganisms, has evolved a minimalist genome while maintaining essential cellular functions .

The partial valS protein typically contains the catalytic core domain responsible for the two-step aminoacylation reaction: activation of valine with ATP and subsequent transfer to the appropriate tRNA. While the full-length enzyme contains additional domains for tRNA recognition and quality control, the partial construct often retains sufficient activity for research applications.

Functional significance includes:

• Retains core aminoacylation activity while being easier to express recombinantly

• Serves as a model system for studying enzymatic mechanisms with reduced structural complexity

• May represent naturally occurring splice variants or proteolytically processed forms found during infection

In research contexts, the partial valS construct facilitates structural studies and inhibitor screening that might be challenging with the full-length protein due to size and stability considerations.

What expression systems are most effective for producing soluble, active recombinant M. pneumoniae valS?

Successful expression of recombinant M. pneumoniae valS requires careful consideration of expression systems to overcome challenges associated with this specialized bacterial protein:

Prokaryotic Expression Systems:

• E. coli BL21(DE3) strains with the pET vector series show good expression levels when combined with solubility-enhancing tags

• Arctic Express or similar cold-adapted strains facilitate expression at lower temperatures (16-18°C), reducing inclusion body formation

• Rosetta or CodonPlus strains address codon bias issues, particularly important as M. pneumoniae uses UGA to encode tryptophan rather than as a stop codon

Expression Optimization Parameters:

• Induction with 0.1-0.5 mM IPTG at lower optical densities (OD₆₀₀ = 0.4-0.6)

• Extended expression periods (16-24 hours) at reduced temperatures

• Supplementation with additional zinc and magnesium ions (1-5 mM) to stabilize the metalloprotein structure

• Inclusion of 5-10% glycerol in growth media to enhance protein solubility

This methodological approach parallels successful strategies used for expressing other M. pneumoniae proteins, such as the P1 adhesion factor and P30 protein, which have been successfully used in recombinant virus construction .

How can researchers verify the functional activity of recombinant M. pneumoniae valS in vitro?

Multiple complementary assays provide robust verification of recombinant valS functionality:

Aminoacylation Activity Assays:

• ATP-PPi Exchange Assay:

  • Measures the first step of aminoacylation (amino acid activation)

  • Detects the enzyme's ability to form valyl-adenylate intermediate

  • Quantified through incorporation of [³²P]-PPi into ATP

• Direct Aminoacylation Assay:

  • Monitors the complete reaction through formation of Val-tRNAᵛᵃˡ

  • Employs either radiolabeled [³H]-valine or [¹⁴C]-valine

  • Can be detected through acid precipitation and scintillation counting

• tRNA Charging Assay:

  • Uses gel electrophoresis to separate charged from uncharged tRNA

  • Northern blotting with specific probes confirms identity of charged tRNA species

  • Acid urea PAGE provides quantitative assessment of charging efficiency

Activity Parameters for Functional Validation:

These validation approaches ensure that recombinant valS maintains catalytic competence comparable to the native enzyme, which is essential for downstream applications in structural biology, inhibitor screening, and immunological studies .

What are the structural differences between M. pneumoniae valS and valS enzymes from other bacterial pathogens?

Comparative structural analysis reveals several distinctive features of M. pneumoniae valS relative to other bacterial homologs:

Domain Architecture Differences:

• Editing Domain:

  • M. pneumoniae valS possesses a streamlined editing domain with decreased size

  • Reduced hydrolytic capacity for misacylated Val-tRNAᴵˡᵉ may influence translation fidelity

  • This contrasts with more extensive editing domains in gram-positive and gram-negative bacterial valS enzymes

• Anticodon Recognition Domain:

  • Demonstrates unique sequence adaptations reflecting M. pneumoniae's codon usage preferences

  • Contains specialized elements for recognizing the distinct tRNA population in this minimal organism

• C-terminal Domain:

  • Typically lacks extended C-terminal regions found in other bacterial valS proteins

  • May affect interaction with other components of the translation machinery

Structural Comparison with Common Bacterial Pathogens:

These structural differences provide opportunities for developing targeted therapeutics against M. pneumoniae infections, which affect both elderly individuals and children and often present as persistent cough and other respiratory symptoms .

What purification challenges are specific to recombinant M. pneumoniae valS and how can they be overcome?

Purification of recombinant M. pneumoniae valS presents several technical challenges requiring specific methodological solutions:

Challenge 1: Nucleic Acid Contamination

• Problem: High affinity for tRNA and DNA leads to co-purification of nucleic acids

• Solution:

  • Include high salt washes (0.8-1M NaCl) during affinity chromatography

  • Incorporate benzonase nuclease (25-50 U/mL) treatment during lysis

  • Apply heparin affinity chromatography as a negative selection step

Challenge 2: Aggregation and Solubility Issues

• Problem: Tendency to form aggregates during concentration and storage

• Solution:

  • Maintain glycerol (10-20%) in all purification buffers

  • Include non-ionic detergents (0.01-0.05% Tween-20) for stability

  • Limit protein concentration below 2-3 mg/mL

  • Add arginine (50-100 mM) as a stabilizing agent

Challenge 3: Metal Ion Dependence

• Problem: Activity loss due to metal chelation during purification

• Solution:

  • Supplement buffers with ZnCl₂ (10-50 μM) and MgCl₂ (1-5 mM)

  • Avoid high concentrations of EDTA or other chelators

  • Use dialysis rather than rapid buffer exchange methods

Optimized Purification Protocol:

• Initial capture: Ni-NTA affinity chromatography with stepped imidazole elution (50, 100, 250 mM)

• Intermediate purification: Ion exchange chromatography (Q-Sepharose at pH 8.0)

• Polishing: Size exclusion chromatography using Superdex 200 in stabilizing buffer

When implemented correctly, this protocol typically yields 3-8 mg of homogeneous protein per liter of bacterial culture with >95% purity as assessed by SDS-PAGE and specific activity of 1-2 μmol/min/mg, suitable for downstream applications including crystallization trials and enzymatic assays .

How can researchers optimize kinetic assays for analyzing M. pneumoniae valS activity with different tRNA substrates?

Kinetic characterization of M. pneumoniae valS with various tRNA substrates requires methodological refinements to address the specific properties of this aminoacyl-tRNA synthetase:

Optimized Aminoacylation Kinetics Protocol:

• tRNA Substrate Preparation:

  • In vitro transcription using T7 RNA polymerase for defined tRNA species

  • Incorporation of ³²P-labeled nucleotides at specific positions for detection

  • Post-transcriptional modification using specific tRNA-modifying enzymes where appropriate

  • Refolding through controlled thermal cycling (65°C → 4°C) in presence of 2-5 mM MgCl₂

• Reaction Condition Optimization:

  • Buffer composition: 50 mM HEPES-KOH (pH 7.5), 10 mM MgCl₂, 50 mM KCl, 1 mM DTT, 4 mM ATP

  • Temperature control at 37°C to reflect physiological conditions of human respiratory tract

  • Pre-incubation of enzyme with ATP before tRNA addition to form enzyme-adenylate complex

  • Inclusion of pyrophosphatase (0.1 U/mL) to prevent product inhibition

• Multiple-Turnover Kinetics Analysis:

  • Initial velocity measurements at various tRNA concentrations (0.1-20 μM)

  • Time-course sampling with quenching in sodium acetate (pH 4.5) containing SDS

  • Separation of charged and uncharged tRNAs via acid-urea PAGE or TLC

  • Quantification via phosphorimaging or scintillation counting

• Data Analysis Approaches:

  • Application of Michaelis-Menten, Lineweaver-Burk, and Eadie-Hofstee plots

  • Global fitting of progress curves to integrated rate equations

  • Comparison of specificity constants (kcat/Km) across different tRNA species

This methodological framework allows researchers to determine whether M. pneumoniae valS displays preferences among various tRNA isoacceptors, which may provide insights into translational regulation during infection and the host-pathogen interaction dynamics observed in different mouse models of M. pneumoniae infection .

What are the most promising approaches for developing selective inhibitors of M. pneumoniae valS?

Development of selective inhibitors targeting M. pneumoniae valS represents a promising strategy for addressing the limitations of current approaches to M. pneumoniae infections, including poor immunogenicity and side effects of vaccines :

Structure-Guided Inhibitor Design Strategies:

• Active Site-Directed Approaches:

  • Rational design of non-hydrolyzable valyl-adenylate analogs

  • Synthesis of compounds that simultaneously occupy amino acid and ATP binding pockets

  • Development of bisubstrate inhibitors linking valine and adenosine derivatives

  • Validation through thermal shift assays (TSA) and isothermal titration calorimetry (ITC)

• Fragment-Based Drug Discovery:

  • Screening of fragment libraries (250-300 Da compounds) by NMR, SPR, or X-ray crystallography

  • Identification of fragment hits binding to different valS sub-pockets

  • Fragment growing, linking, or merging to develop high-affinity molecules

  • Iterative structure determination to guide optimization

• Allosteric Modulation:

  • Identification of M. pneumoniae-specific regulatory sites away from the active site

  • Development of compounds that stabilize inactive conformations

  • Targeting protein-protein interaction surfaces unique to bacterial valS

Experimental Validation Pipeline:

This systematic approach has proven effective for developing inhibitors against aminoacyl-tRNA synthetases in other bacterial pathogens and offers potential for addressing the challenge of M. pneumoniae infections, which disproportionately affect vulnerable populations including the elderly and children with persistent cough and respiratory symptoms .

How does the amino acid composition of different culture media affect the expression and activity of recombinant M. pneumoniae valS?

The amino acid composition of culture media significantly influences both the expression levels and enzymatic activity of recombinant M. pneumoniae valS, necessitating careful optimization:

Media Composition Effects on Expression:

• Defined versus Complex Media:

  • LB medium often yields lower expression due to suboptimal amino acid composition

  • Terrific Broth (TB) with glycerol supplementation increases yield by 1.5-2.5 fold

  • Auto-induction media with controlled glucose/lactose ratios improve expression without IPTG

• Critical Amino Acid Supplementation:

  • Addition of L-valine (5-10 mM) can enhance expression through feedback regulation

  • Supplementation with limiting amino acids (Cys, Met, Trp) at 100-200 mg/L improves yield

  • Excess histidine (1-5 mM) may stabilize metal binding in the active site

• Experimental Optimization Framework:

  • Factorial design experiments to identify significant media components

  • Response surface methodology to determine optimal concentrations

  • Fed-batch approaches with controlled nutrient delivery

Media Effects on Enzymatic Activity and Stability:

These findings parallel observations in M. pneumoniae cultivation studies, where media composition affects bacterial growth characteristics and virulence factor expression. Researchers should consider these media effects when producing recombinant valS for applications such as structural biology, inhibitor screening, or immunogen production for potential vaccine development approaches similar to those using recombinant influenza virus vectors .

What experimental designs best elucidate the role of valS in M. pneumoniae virulence and pathogenicity?

Investigating the role of valS in M. pneumoniae virulence requires multifaceted experimental approaches that address both bacterial and host factors:

In Vitro Experimental Approaches:

• Controlled valS Expression Systems:

  • Development of conditional knockdown strains using inducible antisense RNA

  • CRISPR interference (CRISPRi) targeting valS promoter for partial repression

  • Analysis of growth kinetics, morphology, and cytadhesin expression under valS limitation

• Infection Models with Human Respiratory Epithelial Cells:

  • Air-liquid interface cultures of primary bronchial epithelial cells

  • Measurement of cytopathic effects and ciliary dysfunction

  • Quantification of pro-inflammatory cytokine production (IL-1α, IL-6, IL-12p40)

  • Comparison between wild-type and valS-modulated M. pneumoniae strains

• Translational Fidelity Assessment:

  • Reporter systems measuring mistranslation rates

  • Analysis of protein quality control responses

  • Correlation between translation errors and antigenic variation

In Vivo Models with Strategic Selection of Mouse Strains:

Based on susceptibility data from mouse models, certain strains demonstrate differential responses to M. pneumoniae infection. For valS-focused studies, researchers should consider:

• DBA/2 mice: Show significantly higher bacterial loads in bronchoalveolar lavage fluid (BALF) and increased susceptibility, making them suitable for studying valS inhibitors in vivo

• BALB/c mice: Exhibit intermediate susceptibility with robust immune responses

• C57BL/6J mice: Display lower susceptibility, useful for comparative studies

Experimental Readouts for Virulence Assessment:

This comprehensive experimental design strategy enables researchers to establish whether valS functions extend beyond house-keeping protein synthesis to directly influence virulence, potentially through effects on adhesin expression, antigenic variation, or stress responses during host colonization .

How can researchers incorporate valS epitopes into viral vector systems for vaccine development?

Development of recombinant viral vectors carrying M. pneumoniae valS epitopes represents a promising vaccination strategy that builds upon demonstrated success with other M. pneumoniae antigens:

Vector Construction Methodology Based on Influenza Virus Platform:

• Epitope Selection and Optimization:

  • Computational prediction of valS T-cell and B-cell epitopes using immunoinformatics tools

  • Experimental validation through peptide-MHCII binding assays and T-cell activation studies

  • Optimization of epitope sequences for enhanced immunogenicity while preserving native structure

• Vector Design Strategy:

  • Insertion of valS epitope sequences into the nonstructural protein (NS) gene of influenza virus

  • Construction of recombinant vectors (pHW2000 plasmids) containing NS-valS fusion constructs

  • Co-transfection with the remaining 7 fragments of influenza virus (e.g., PR8 strain) into HEK293T cells

• Virus Production Protocol:

  • Propagation in embryonated chicken eggs following established methods

  • Verification through RT-PCR and sequencing to confirm genetic stability

  • Assessment of hemagglutination titers across multiple passages

  • Electron microscopy verification of viral particle morphology

This approach directly parallels successful methodologies demonstrated with M. pneumoniae P1 and P30 antigens, where recombinant influenza viruses rFLU-P1a and rFLU-P30a maintained genetic stability over multiple passages and displayed typical influenza virus morphology .

Immunological Evaluation Framework:

This vaccine development approach addresses the limitations of current M. pneumoniae vaccination strategies, including poor immunogenicity and side effects of inactivated or attenuated vaccines, potentially providing protection for vulnerable populations including children and the elderly who are particularly susceptible to M. pneumoniae respiratory infections .

What structural biology techniques provide the most useful information for understanding valS catalytic mechanisms?

A comprehensive structural biology approach combining multiple techniques provides the most complete understanding of M. pneumoniae valS catalytic mechanisms:

X-ray Crystallography for High-Resolution Static Structures:

• Sample Preparation Optimization:

  • Screening for stabilizing ligands (ATP, valine, non-hydrolyzable analogs)

  • Surface entropy reduction through strategic mutation of flexible charged residues

  • Limited proteolysis to identify stable core domains

• Crystallization Strategy:

  • Sparse matrix screening followed by optimization of hit conditions

  • Addition of molecular crowding agents (PEG, glycerol) to mimic cellular environment

  • Use of microseeding techniques to improve crystal quality

• Data Collection and Processing:

  • Synchrotron radiation for high-resolution diffraction data (≤2.0 Å)

  • Multiple anomalous dispersion (MAD) phasing using selenomethionine-labeled protein

  • Molecular replacement using related bacterial valS structures as search models

Cryo-Electron Microscopy for Conformational Ensembles:

• Sample Vitrification Optimization:

  • Grid surface treatment to control protein orientation

  • Screening of buffer conditions to minimize preferential orientations

  • Use of detergents below critical micelle concentration to prevent aggregation

• Data Collection Parameters:

  • Energy-filtered imaging to enhance contrast

  • Dose fractionation to minimize radiation damage

  • Tilted data collection to address preferred orientation issues

• Computational Analysis:

  • 3D classification to resolve conformational heterogeneity

  • Focused refinement on catalytic domains

  • Time-resolved approaches using rapid mixing and vitrification

Solution NMR for Dynamics and Interaction Studies:

• Sample Optimization:

  • Isotopic labeling schemes (¹⁵N, ¹³C, ²H) for domains under 25 kDa

  • TROSY-based methods for larger constructs

  • Selective methyl labeling against deuterated background

• Experimental Approaches:

  • Backbone assignment using triple resonance experiments

  • Relaxation dispersion for μs-ms timescale dynamics

  • Chemical shift perturbation to map ligand binding sites

  • Paramagnetic relaxation enhancement to detect transient interactions

Integrative Structural Biology Workflow:

This multi-technique approach has proven invaluable for understanding the mechanisms of aminoacyl-tRNA synthetases and can provide crucial insights for rational inhibitor design targeting M. pneumoniae valS .

How can protein-protein interaction networks involving valS be mapped in the context of M. pneumoniae's minimal genome?

Mapping protein-protein interactions (PPIs) involving valS in M. pneumoniae requires specialized approaches that account for the organism's minimal genome and challenging cultivation characteristics:

In Vivo Interaction Mapping Strategies:

• Proximity-Dependent Labeling:

  • BioID fusion to valS for biotinylation of proximal proteins

  • APEX2-valS fusion for peroxidase-mediated labeling in millisecond timescales

  • TurboID for rapid biotin labeling under native conditions

  • MS identification of biotinylated proteins followed by bioinformatic filtering against controls

• Crosslinking Mass Spectrometry (XL-MS):

  • Application of cell-permeable crosslinkers (DSS, formaldehyde) to intact M. pneumoniae

  • Enrichment of valS-containing complexes via affinity purification

  • MS/MS analysis with specialized search algorithms for crosslinked peptides

  • Structural validation through molecular modeling of identified interactions

• Fluorescence-Based Approaches:

  • Split-GFP complementation to visualize interactions in live cells

  • FRET pairs fused to valS and candidate interactors

  • Multiplexed epitope tagging for co-localization studies

Interactome Analysis Framework:

Expected Interaction Categories for valS:

• Translation machinery components:

  • Elongation factors

  • Ribosomal proteins

  • Other aminoacyl-tRNA synthetases forming multi-synthetase complexes

• Metabolic enzymes:

  • Valine biosynthesis pathway components

  • ATP regeneration systems

  • tRNA modification enzymes

• Stress response and quality control:

  • Chaperones

  • Proteases

  • Stress response regulators

This comprehensive approach is particularly relevant given M. pneumoniae's reduced genome, where moonlighting functions of proteins like valS likely compensate for the limited gene repertoire, potentially contributing to the pathogen's ability to cause persistent respiratory infections in both children and the elderly .

What methodologies can differentiate between direct antimicrobial effects on valS versus downstream cellular responses?

Distinguishing direct inhibition of M. pneumoniae valS from secondary cellular effects requires a multifaceted experimental approach:

Direct Target Engagement Assessment:

• Thermal Shift Assays (TSA/DSF):

  • Measurement of protein thermal stability in presence of inhibitors

  • Dose-dependent shifts in melting temperature (Tm)

  • Competitive displacement assays with natural substrates

  • Counterscreening against human ValRS to establish selectivity

• Enzyme Kinetic Analysis:

  • Determination of inhibition modality (competitive, noncompetitive, uncompetitive)

  • Measurement of Ki values across substrate concentration ranges

  • Progress curve analysis to detect time-dependent inhibition

  • Substrate protection studies to confirm binding site

• Direct Binding Measurements:

  • Isothermal titration calorimetry (ITC) for thermodynamic parameters

  • Surface plasmon resonance (SPR) or bio-layer interferometry (BLI) for binding kinetics

  • Microscale thermophoresis (MST) for solution-based binding analysis

  • NMR-based fragment screening and binding site mapping

Cellular Response Characterization:

Validation in Mouse Infection Models:

Building on established susceptibility differences between mouse strains, researchers can employ DBA/2 mice (which show higher bacterial loads) and BALB/c mice (with intermediate susceptibility) to evaluate:

• Time-dependent effects of valS inhibitors on bacterial load

• Correlation between in vitro target engagement potency and in vivo efficacy

• Modulation of inflammatory markers (IL-1α, IL-6, IL-12p40) in BALF

• Effects on neutrophil recruitment to distinguish direct antimicrobial activity from immunomodulation

This comprehensive framework enables rigorous validation of valS-targeting compounds as potential therapeutics for M. pneumoniae infections, addressing the limitations of current treatment approaches for this respiratory pathogen that causes persistent cough and respiratory symptoms in vulnerable populations .